sandrine Chamayou

Dr. sandrine Chamayou

Centro HERA - Unità de Medicina della Riproduzione, Catania, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2013 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Open access
PDF file
SCsandrine Chamayou
sandrine Chamayou
PPPasquale Patrizio
Pasquale Patrizio
GSGiorgia Storaci
Giorgia Storaci
VTVenera Tomaselli
Venera Tomaselli
CACarmelita Alecci
Carmelita Alecci
AGAntonino Guglielmino
Antonino Guglielmino
Purpose Embryo kinetics analysis is an emerging tool for selecting embryo(s) for transfer. The aim of the present study was to determine morphokinetic parameters easily usable in the laboratory and predictive of embryo development and, most importantly, of embryo competence in producing a clinical pregnancy after day 5 transfer. Methods A retrospective time-lapse monitoring analysis of morphokinetic parameters for 72 fully implanted embryos (group A) were compared to 106 non-implanted embryos (group B), and to 66 embryos with arrested development from the same pool of group A. All the embryos were from 78 patients undergoing ICSI treatment and day 5 embryo transfers. Results A day 3 embryo will develop into a viable blastocyst if the following ranges of morphokinetic parameters are met: t1 (between 18.4 h and 30.9 h post-ICSI), t2 (21.4–34.8 h), t4 (33.1–57.2 h), t7 (46.1–82.5 h), t8 (46.4–97.8 h), tC-tF (7.7–22.9 h) and s3 (0.7–30.8 h). On day 5 embryos with the highest probability to implant are those with a cc3 between 9.7 h and 21 h. Conclusions Morphokinetic parameters are helpful to make appropriate decisions for the disposition of each embryo. It is recommended that each laboratory should determine its own ranges of in vitro development (IVD-MKP) and implantation-associated (IMP-MKP) morphokinetic parameters.

12 February 2025 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
luigi montanoluigi montano
luigi montano
SRSalvatore Raimondo
Salvatore Raimondo
Marina PiscopoMarina Piscopo
Marina Piscopo
Maria RicciardiMaria Ricciardi
Maria Ricciardi
AGAntonino Guglielmino
Antonino Guglielmino
Oriana MottaOriana Motta
Oriana Motta
Several studies have assessed the presence of microplastics (MPs) in human biological fluids and tissues highlighting potential health risks associated to oxidative stress, inflammation, immune dysfunction, neurotoxicity and reprotoxicity. However, only few studies have evaluated MP presence and effects in ovarian tissues of mammalians and, to date, no studies have detected MPs in human ovarian follicular fluids. Based on these premises, in this study, 18 women (undergoing assisted reproductive treatment at In Vitro Fertilisation center in Salerno, Southern Italy) were selected to assess the presence of MPs in follicular fluid. Plastic particles < 10 µm were measured using Scanning Electron Microscopy (SEM) coupled with an EDX (X Energy Dispersion) detector. MPs (size <10 µm) were detected in 14 out of 18 samples of follicular fluid, with an average concentration of 2191 particles/mL (0-7181particles/mL) and with a mean diameter of 4.48 µm (3.18-5.54 µm). Moreover, a significant correlation between MP concentration in follicular fluid samples and Follicle-Stimulating Hormone (FSH) (p-value <0.05), as well as a weak (non-significant) correlation with Body Mass Index (BMI), age and 17β-estradiol (E2), was found. On the contrary, no correlation with anti-Müllerian Hormone (AMH), fertilization outcomes, miscarriages, or live birth was observed. Since several studies on animal models have demonstrated the negative effects of MPs on ovarian function, the present study, that verified for the first time the presence of MPs in human follicular fluid, is of great significance for the scientific community in terms of raising awareness of the impact that these increasingly pervasive emerging contaminants have on reproductive function and human health.

1 April 2011 in Cryobiology
Verified
Journal Article
Closed access
SCsandrine Chamayou
sandrine Chamayou
GBG. Bonaventura
G. Bonaventura
CAC. Alecci
C. Alecci
Daniele TibulloDaniele Tibullo
Daniele Tibullo
FRFrancesco Di Raimondo
Francesco Di Raimondo
MBM.L. Barcellona
M.L. Barcellona

9 January 2017 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Open access
PDF file
SCsandrine Chamayou
sandrine Chamayou
MSMaria Sicali
Maria Sicali
CACarmelita Alecci
Carmelita Alecci
CRCarmen Ragolia
Carmen Ragolia
ALAnnalisa Liprino
Annalisa Liprino
AGAntonino Guglielmino
Antonino Guglielmino
In a preimplantation genetic diagnosis for aneuploidy (PGD-A) program, the more embryos available for biopsy, consequently increases the chances of obtaining euploid embryos to transfer. The aim was to increase the number of viable euploid blastocysts in patients undergoing PGD-A using fresh oocytes together with previously accumulated vitrified oocytes.

14 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SCsandrine Chamayou
sandrine Chamayou
FGFilippo Giacone
Filippo Giacone
Rossella CannarellaRossella Cannarella
Rossella Cannarella
AGAntonino Guglielmino
Antonino Guglielmino
The intracytoplasmic sperm injection (ICSI) technique was invented to solve severe male infertility due to altered sperm parameters. Nowadays, it is applied worldwide for the treatment of couple infertility. ICSI is performed with any available spermatozoon from surgery or ejaculated samples, whatever are the sperm motility, morphology or quantity. The aim of the present review was to study if embryo development and kinetics would be modified by (1) ICSI under the technical aspects, (2) the micro-injected spermatozoa in connection with male infertility. From published data, it can be seen that ICSI anticipates the zygote kinetics Furthermore, because fertilization rate is higher in ICSI compared to conventional in vitro fertilization (IVF), more blastocysts are obtained for clinical use in ICSI. Sperm and spermatozoa characteristics, such as sperm parameters, morphology and vitality, DNA content (levels of sperm DNA fragmentation, microdeletions, and chromosomal abnormalities), RNA content, epigenetics, and sperm recovery site (testicular, epididymis, and ejaculated), have an impact on fertilization and blastocyst rates and embryo kinetics in different ways. Even though ICSI is the most common solution to solve couples’ infertility, the causes of male infertility are crucial in building a competent spermatozoa that will contribute to normal embryonic development and healthy offspring.

26 July 2021 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
SCsandrine Chamayou
sandrine Chamayou
CRCarmen Ragolia
Carmen Ragolia
CACarmelita Alecci
Carmelita Alecci
GSGiorgia Storaci
Giorgia Storaci
SRSimona Romano
Simona Romano
AGAntonino Guglielmino
Antonino Guglielmino
Background: Which fertilization method, between ICSI and IVF in split insemination treatments, has the highest clinical efficiency in producing clinically usable blastocyst? Methods: 211 infertile couples underwent split insemination treatments for a non-severe male factor. 1300 metaphase II (MII) oocytes were inseminated by conventional IVF and 1302 MII oocytes were micro-injected with the same partner’s semen. Embryo development until blastocyst stage on day V and clinical outcomes were valuated trough conventional key performance indicators (KPI), and new KPIs such as blastocyst rate per used MII oocytes and the number of MII oocytes to produce one clinically usable blastocyst from ICSI and IVF procedures. Results: The results were globally analyzed and according to ovarian stimulation protocol, infertility indication, and female age. The conventional KPI were online with the expected values from consensus references. From global results, 2.3 MII oocyte was needed to produce one clinically usable blastocyst after ICSI compared to 2.9 MII oocytes in IVF. On the same way, more blastocysts for clinical use were produced from fewer MII oocytes in ICSI compared to IVF in all sub-groups. Conclusions: In split insemination treatments, the yield of clinically usable blastocysts was always superior in ICSI compared to IVF. The new KPI "number of needed oocytes to produce one clinically usable embryo" tests the clinical efficiency of the IVF laboratory.